Latest & greatest articles for lung cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on lung cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on lung cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for lung cancer

41. Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. (PubMed)

Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. BACKGROUND: Standard first-line therapy for metastatic, squamous non-small-cell lung cancer (NSCLC) is platinum-based chemotherapy or pembrolizumab (for patients with programmed death ligand 1 [PD-L1] expression on ≥50% of tumor cells). More recently, pembrolizumab plus chemotherapy was shown to significantly prolong overall survival among patients with nonsquamous NSCLC. METHODS: In this double-blind, phase 3 trial, we (...) randomly assigned, in a 1:1 ratio, 559 patients with untreated metastatic, squamous NSCLC to receive 200 mg of pembrolizumab or saline placebo for up to 35 cycles; all the patients also received carboplatin and either paclitaxel or nanoparticle albumin-bound [nab]-paclitaxel for the first 4 cycles. Primary end points were overall survival and progression-free survival. RESULTS: After a median follow-up of 7.8 months, the median overall survival was 15.9 months (95% confidence interval [CI], 13.2

2018 NEJM

42. Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer. (PubMed)

Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer. BACKGROUND: Brigatinib, a next-generation anaplastic lymphoma kinase (ALK) inhibitor, has robust efficacy in patients with ALK-positive non-small-cell lung cancer (NSCLC) that is refractory to crizotinib. The efficacy of brigatinib, as compared with crizotinib, in patients with advanced ALK-positive NSCLC who have not previously received an ALK inhibitor is unclear. METHODS: In an open-label, phase 3 trial, we randomly

2018 NEJM

43. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. (PubMed)

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. BACKGROUND: Enhancing tumor-specific T-cell immunity by inhibiting programmed death ligand 1 (PD-L1)-programmed death 1 (PD-1) signaling has shown promise in the treatment of extensive-stage small-cell lung cancer. Combining checkpoint inhibition with cytotoxic chemotherapy may have a synergistic effect and improve efficacy. METHODS: We conducted this double-blind, placebo-controlled, phase 3 trial to evaluate (...) atezolizumab plus carboplatin and etoposide in patients with extensive-stage small-cell lung cancer who had not previously received treatment. Patients were randomly assigned in a 1:1 ratio to receive carboplatin and etoposide with either atezolizumab or placebo for four 21-day cycles (induction phase), followed by a maintenance phase during which they received either atezolizumab or placebo (according to the previous random assignment) until they had unacceptable toxic effects, disease progression

2018 NEJM

44. Study protocol of a randomized controlled trial comparing integrative body-mind-spirit intervention and cognitive behavioral therapy in fostering quality of life of patients with lung cancer and their family caregivers. (PubMed)

Study protocol of a randomized controlled trial comparing integrative body-mind-spirit intervention and cognitive behavioral therapy in fostering quality of life of patients with lung cancer and their family caregivers. 29400621 2018 09 25 2018 12 02 2376-1415 15 3 2018 May-Jun Journal of evidence-informed social work J Evid Inf Soc Work Study protocol of a randomized controlled trial comparing integrative body-mind-spirit intervention and cognitive behavioral therapy in fostering quality (...) of life of patients with lung cancer and their family caregivers. 258-276 10.1080/23761407.2018.1435325 Compared to cancers at other sites, lung cancer often results in greater psychosocial distress to both the patients and their caregivers, due to the poor prognosis and survival rate, as well as the heavy symptom burden. In recent years, making protocols of proposed or on-going studies publicly available via clinical trial registries and/or peer-reviewed journals has benefited health sciences with timely

2018 Journal of evidence-informed social work

45. Low pre‐treatment nutritional index is significantly related to poor outcomes in small cell lung cancer (PubMed)

Low pre‐treatment nutritional index is significantly related to poor outcomes in small cell lung cancer 30209884 2018 12 07 1759-7714 9 11 2018 Nov Thoracic cancer Thorac Cancer Low pre-treatment nutritional index is significantly related to poor outcomes in small cell lung cancer. 1483-1491 10.1111/1759-7714.12862 The importance of nutritional status and chronic inflammation has been emphasized in cancer. We investigated the impact of Onodera's prognostic nutritional index (OPNI) on clinical (...) outcomes in small cell lung cancer (SCLC) patients. Data from 220 SCLC patients treated with first-line platinum-based chemotherapy from 2006 to 2017 were retrospectively reviewed. The OPNI was calculated as 10 × serum albumin level (g/dL) + 0.005 × absolute lymphocyte count (/mm 3 ). Patients with an OPNI of > 45, 40-45, or < 40 were categorized in high, intermediate, or low OPNI groups, respectively. The proportion of non-responders to first-line therapy increased as the OPNI decreased (high

Full Text available with Trip Pro

2018 Thoracic cancer

46. Comparable immunoreactivity rates of PD‐L1 in archival and recent specimens from non‐small cell lung cancer (PubMed)

Comparable immunoreactivity rates of PD‐L1 in archival and recent specimens from non‐small cell lung cancer 30209885 2018 12 07 1759-7714 9 11 2018 Nov Thoracic cancer Thorac Cancer Comparable immunoreactivity rates of PD-L1 in archival and recent specimens from non-small cell lung cancer. 1476-1482 10.1111/1759-7714.12861 Molecular targeted therapy including the use of monoclonal antibodies directed against the immune checkpoints PD-L1 and PD-1 receptor have remarkably improved (...) the therapeutic response and survival of cancer patients. The tumor expression level of PD-L1 can predict the response rate to checkpoint inhibitors. We evaluated whether the time interval between tumor tissue sampling/paraffinization and immunohistochemistry affects the staining level of PD-L1 in non-small cell lung cancer (NSCLC). This study comprised 137 patients with NSCLC. Tumors were stained with 22C3 or 28-8 antibodies. There was a significant correlation between the immunoreactivity rate of tumor

Full Text available with Trip Pro

2018 Thoracic cancer

47. Immune checkpoint inhibitors for every patient with non-small cell lung cancer? Update on immunotherapy in patients with lung cancer (PubMed)

Immune checkpoint inhibitors for every patient with non-small cell lung cancer? Update on immunotherapy in patients with lung cancer 30345082 2018 10 22 2059-7029 3 6 2018 ESMO open ESMO Open Immune checkpoint inhibitors for every patient with non-small cell lung cancer? Update on immunotherapy in patients with lung cancer. e000429 10.1136/esmoopen-2018-000429 Vansteenkiste Johan F JF Respiratory Oncology Unit and Trial Unit, Department of Respiratory Diseases, University Hospitals KU Leuven

Full Text available with Trip Pro

2018 ESMO open

48. Quantitative proteomic analysis of mitochondrial proteins differentially expressed between small cell lung cancer cells and normal human bronchial epithelial cells (PubMed)

Quantitative proteomic analysis of mitochondrial proteins differentially expressed between small cell lung cancer cells and normal human bronchial epithelial cells 30198174 2018 12 07 1759-7714 9 11 2018 Nov Thoracic cancer Thorac Cancer Quantitative proteomic analysis of mitochondrial proteins differentially expressed between small cell lung cancer cells and normal human bronchial epithelial cells. 1366-1375 10.1111/1759-7714.12839 Small cell lung cancer (SCLC) is highly aggressive (...) and is associated with a dismal prognosis. However, there are no clinically recognized biomarkers for early diagnosis. In this study, we used quantitative proteomics to build differential mitochondrial protein profiles that may be used for early diagnosis and investigated the pathogenesis of lung cancer. We cultured SCLC cells (NCI-H446) and normal human bronchial epithelial cells (16-HBE); mitochondria were extracted and purified using differential and Percoll density gradient centrifugation. Subsequently, we

Full Text available with Trip Pro

2018 Thoracic cancer

49. Extra cost of brain metastases (BM) in patients with non-squamous non-small cell lung cancer (NSCLC): a French national hospital database analysis (PubMed)

Extra cost of brain metastases (BM) in patients with non-squamous non-small cell lung cancer (NSCLC): a French national hospital database analysis 30233822 2018 11 14 2059-7029 3 6 2018 ESMO open ESMO Open Extra cost of brain metastases (BM) in patients with non-squamous non-small cell lung cancer (NSCLC): a French national hospital database analysis. e000414 10.1136/esmoopen-2018-000414 To assess the incremental cost associated with the management of patients with primary non-squamous non (...) -small cell lung cancer (NSCLC) with brain metastases at the time of diagnosis. Data were extracted from the French Hospital medical information database (Programme de Médicalisation des Systèmes d'Information (PMSI)). Patients with non-squamous NSCLC were identified through a diagnosis of lung cancer and a prescription of bevacizumab or pemetrexed. All such patients hospitalised with lung cancer for the first time in 2013 and with metastases identified at the first hospitalisation were eligible. Two

Full Text available with Trip Pro

2018 ESMO open

50. Temporal Trends and Geographic Patterns of Lung Cancer Incidence by Histology in Thailand, 1990 to 2014 (PubMed)

Temporal Trends and Geographic Patterns of Lung Cancer Incidence by Histology in Thailand, 1990 to 2014 30192698 2018 12 07 2378-9506 4 2018 Aug Journal of global oncology J Glob Oncol Temporal Trends and Geographic Patterns of Lung Cancer Incidence by Histology in Thailand, 1990 to 2014. 1-29 10.1200/JGO.18.00013 Purpose Lung cancer is one of the most common cancers worldwide and in Thailand. We characterize and forecast region-specific patterns of lung cancer incidence by histology and sex (...) . Methods We analyzed lung cancer incidence trends in Thailand by histology (adenocarcinoma [AdC]; squamous cell carcinoma [SCC]; and large-cell, small-cell, and other carcinomas) from 1990 to 2014 in four cancer registries in three regions (north, Chiang Mai Province and Lampang Province; northeast: Khon Kaen Province; south: Songkhla Province). Annual percent change (APC) was calculated to quantify the incidence rate trends using joinpoint regression. Age-period-cohort models were used to examine

Full Text available with Trip Pro

2018 Journal of global oncology

51. New drugs in thoracic oncology: needs and knowledge – an online ERS Lung Cancer Assembly survey (PubMed)

New drugs in thoracic oncology: needs and knowledge – an online ERS Lung Cancer Assembly survey 30186846 2018 11 14 2312-0541 4 3 2018 Jul ERJ open research ERJ Open Res New drugs in thoracic oncology: needs and knowledge - an online ERS Lung Cancer Assembly survey. 00040-2018 10.1183/23120541.00040-2018 In the last decade, systemic therapy for advanced lung cancer has become diverse, complex and personalised. These new therapies (monoclonal antibodies, tyrosine kinase inhibitors (TKIs (...) in an online platform reporting new drugs' toxicities. Despite a large amount of publicity and integration of new drugs into therapeutic algorithms and clinical guidelines, physicians taking care of lung cancer patients have a need for up-to-date information on systemic therapy toxicity management and legal constraints. Berghmans Thierry T Dept of Intensive Care, and Oncological Emergencies and Thoracic Oncology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium. Evison Matthew M

Full Text available with Trip Pro

2018 ERJ open research

52. Elevated Serum Megakaryocyte Potentiating Factor as a Predictor of Poor Survival in Patients with Mesothelioma and Primary Lung Cancer (PubMed)

Elevated Serum Megakaryocyte Potentiating Factor as a Predictor of Poor Survival in Patients with Mesothelioma and Primary Lung Cancer 30370398 2018 11 14 2475-7241 3 2 2018 Sep The journal of applied laboratory medicine J Appl Lab Med Elevated Serum Megakaryocyte Potentiating Factor as a Predictor of Poor Survival in Patients with Mesothelioma and Primary Lung Cancer. 166-177 10.1373/jalm.2017.025015 There is an urgent need for a companion assay to work with mesothelin-targeted therapeutic (...) agents and for noninvasive and accurate prognostication of malignant mesothelioma (MM) patients. We report the development and validation of a blood-based assay for megakaryocyte potentiating factor (MPF) and the evaluation of its effectiveness for prognosis in MM and lung cancer patients. Using electrochemiluminescence technology, we developed a sensitive MPF assay and performed both analytical and clinical validations. Further, the effectiveness of the MPF assay in predicting prognosis

Full Text available with Trip Pro

2018 The journal of applied laboratory medicine

53. Association between age, deprivation and specific comorbid conditions and the receipt of major surgery in patients with non-small cell lung cancer in England: A population-based study

Association between age, deprivation and specific comorbid conditions and the receipt of major surgery in patients with non-small cell lung cancer in England: A population-based study 30100577 2018 08 13 1468-3296 2018 Aug 12 Thorax Thorax Association between age, deprivation and specific comorbid conditions and the receipt of major surgery in patients with non-small cell lung cancer in England: A population-based study. thoraxjnl-2017-211395 10.1136/thoraxjnl-2017-211395 We investigated (...) socioeconomic disparities and the role of the main prognostic factors in receiving major surgical treatment in patients with lung cancer in England. Our study comprised 31 351 patients diagnosed with non-small cell lung cancer in England in 2012. Data from the national population-based cancer registry were linked to Hospital Episode Statistics and National Lung Cancer Audit data to obtain information on stage, performance status and comorbidities, and to identify patients receiving major surgical treatment

Full Text available with Trip Pro

2018 EvidenceUpdates

54. Efficacy of Endosonographic Procedures in Mediastinal Restaging of Lung Cancer After Neoadjuvant Therapy: A Systematic Review and Diagnostic Accuracy Meta-Analysis

Efficacy of Endosonographic Procedures in Mediastinal Restaging of Lung Cancer After Neoadjuvant Therapy: A Systematic Review and Diagnostic Accuracy Meta-Analysis 29684314 2018 07 25 1931-3543 154 1 2018 Jul Chest Chest Efficacy of Endosonographic Procedures in Mediastinal Restaging of Lung Cancer After Neoadjuvant Therapy: A Systematic Review and Diagnostic Accuracy Meta-Analysis. 99-109 S0012-3692(18)30585-3 10.1016/j.chest.2018.04.014 The optimal modality for restaging the mediastinum (...) following neoadjuvant therapy for lung cancer remains unclear. Surgical methods are currently considered the reference standard. The present study evaluates the role of endosonographic techniques for mediastinal restaging in lung cancer. A systematic review of PubMed and Embase databases was performed to identify studies using endoscopic ultrasound, endobronchial ultrasound, or a combination of the two for mediastinal restaging following induction therapy for stage III lung cancer. The quality

2018 EvidenceUpdates

55. Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer (PubMed)

Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer 29906251 2018 08 16 1527-7755 36 23 2018 Aug 10 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small (...) -Cell Lung Cancer. 2386-2394 10.1200/JCO.2018.77.7672 Purpose Both temozolomide (TMZ) and poly (ADP-ribose) polymerase (PARP) inhibitors are active in small-cell lung cancer (SCLC). This phase II, randomized, double-blind study evaluated whether addition of the PARP inhibitor veliparib to TMZ improves 4-month progression-free survival (PFS). Patients and Methods A total of 104 patients with recurrent SCLC were randomly assigned 1:1 to oral veliparib or placebo 40 mg twice daily, days 1 to 7

Full Text available with Trip Pro

2018 EvidenceUpdates

56. Cisplatin-Based First-Line Treatment of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: Joint Analysis of MILES-3 and MILES-4 Phase III Trials

Cisplatin-Based First-Line Treatment of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: Joint Analysis of MILES-3 and MILES-4 Phase III Trials 30028656 2018 08 29 1527-7755 36 25 2018 Sep 01 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. Cisplatin-Based First-Line Treatment of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: Joint Analysis of MILES-3 and MILES-4 Phase III Trials. 2585-2592 10.1200/JCO (...) .2017.76.8390 Purpose To test the efficacy of adding cisplatin to first-line treatment for elderly patients with advanced non-small-cell lung cancer (NSCLC) within a combined analysis of two parallel phase III trials, MILES-3 and MILES-4. Patients and Methods Patients with advanced NSCLC who were older than age 70 years with Eastern Cooperative Oncology Group performance status 0 to 1 were randomly assigned to gemcitabine or pemetrexed, without or with cisplatin. In each trial, 382 events were required

2018 EvidenceUpdates

57. Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations

Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations 29864379 2018 07 27 1527-7755 36 22 2018 Aug 01 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR (...) -Activating Mutations. 2244-2250 10.1200/JCO.2018.78.7994 Purpose ARCHER 1050, a randomized, open-label, phase III study of dacomitinib versus gefitinib in treatment-naïve patients with advanced non-small-cell lung cancer (NSCLC) and activating mutations in EGFR, reported significant improvement in progression-free survival with dacomitinib. The mature overall survival (OS) analysis for the intention-to-treat population is presented here. Patients and Methods In this multinational, multicenter study

2018 EvidenceUpdates

58. New method of lung cancer detection by saliva test using surface‐enhanced Raman spectroscopy (PubMed)

New method of lung cancer detection by saliva test using surface‐enhanced Raman spectroscopy 30168669 2018 12 07 1759-7714 9 11 2018 Nov Thoracic cancer Thorac Cancer New method of lung cancer detection by saliva test using surface-enhanced Raman spectroscopy. 1556-1561 10.1111/1759-7714.12837 Surface-enhanced Raman spectroscopy (SERS) is a surface-sensitive technique that enhances Raman scattering by molecules adsorbed on nanostructures. The advantages of using SERS include high detection (...) sensibility and fast analysis, thus it is a potentially promising tool for sensing metabolic cancer molecules in trace amounts. To explore this new method of lung cancer detection, we analyzed saliva samples from 61 lung cancer patients and 66 healthy controls. An SERS system and a nano-modified chip were used in this study. Statistics were analyzed using support vector machine (SVM) and random forest algorithms. The leave-one-out algorithm was used based on SVM results to analyze differences in saliva

Full Text available with Trip Pro

2018 Thoracic cancer

59. Safety of endobronchial ultrasound‐guided transbronchial needle aspiration in patients with lung cancer within a year after percutaneous coronary intervention (PubMed)

Safety of endobronchial ultrasound‐guided transbronchial needle aspiration in patients with lung cancer within a year after percutaneous coronary intervention 30156380 2018 12 07 1759-7714 9 11 2018 Nov Thoracic cancer Thorac Cancer Safety of endobronchial ultrasound-guided transbronchial needle aspiration in patients with lung cancer within a year after percutaneous coronary intervention. 1390-1397 10.1111/1759-7714.12846 Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS (...) -TBNA) may be necessary for patients with incidental lung cancer during or after coronary intervention. Although EBUS-TBNA is quite safe, the safety in patients who recently received percutaneous coronary intervention (PCI) has not been demonstrated. The aim of this study was to assess the safety of EBUS-TBNA in patients with lung cancer who underwent PCI within one year. We retrospectively reviewed the medical records of 24 patients who underwent EBUS-TBNA within one year after PCI between May 2009

Full Text available with Trip Pro

2018 Thoracic cancer

60. Comparison between computed tomography‐guided percutaneous microwave ablation and thoracoscopic lobectomy for stage I non‐small cell lung cancer (PubMed)

Comparison between computed tomography‐guided percutaneous microwave ablation and thoracoscopic lobectomy for stage I non‐small cell lung cancer 30152596 2018 12 07 1759-7714 9 11 2018 Nov Thoracic cancer Thorac Cancer Comparison between computed tomography-guided percutaneous microwave ablation and thoracoscopic lobectomy for stage I non-small cell lung cancer. 1376-1382 10.1111/1759-7714.12842 The study was conducted to investigate the effectiveness and cost of computed tomography (CT (...) )-guided percutaneous microwave ablation (MWA) and thoracoscopic lobectomy for stage I non-small cell lung cancer (NSCLC). We retrospectively analyzed the data of 46 and 85 patients with stage I NSCLC treated with CT-guided percutaneous MWA or thoracoscopic lobectomy, respectively, at our center from July 2013 to June 2015. Overall survival (OS), disease-free survival (DFS), local control rate, hospital stay, and cost were evaluated. Survival curves were constructed using the Kaplan-Meier method

Full Text available with Trip Pro

2018 Thoracic cancer